This is a prospective, single-arm, phase II clinical study designed to evaluate the efficacy and safety of surufatinib and tislelizumab in combination with concurrent chemoradiotherapy, followed by consolidation therapy with tislelizumab plus surufatinib, in patients with unresectable, locally advanced stage III non-small cell lung cancer (NSCLC).
A written and dated informed consent form must be obtained prior to the initiation of any study-specific procedures.
Male or female patients aged 18 to 75 years.
Histologically or cytologically confirmed locally advanced, unresectable non-small cell lung cancer (NSCLC) (Stage IIIA-IIIC).
Tumor sample requirement: Adequate archival, unstained tumor tissue samples must be provided for analysis.
Participation in another clinical study, unless it is an observational (non-interventional) study.
Histological diagnosis of combined small cell and non-small cell lung cancer.
Presence of EGFR or ALK driver gene mutations.
Any condition that may affect oral medication administration (e.g., dysphagia, chronic diarrhea, bowel obstruction).
Sun Yat-sen University
Lead sponsor